BioNTech launches first human test of BNT317 against advanced cancers
NCT ID NCT06750185
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if BNT317 will actually fight cancer, but this study is a necessary first step.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BNT317 (an experimental biologic drug given by intravenous infusion)
What this could lead to
If this early trial shows BNT317 is safe and tolerable, it could pave the way for larger studies to see if it helps shrink or control advanced solid tumors.
What could go wrong
This is a very early, first-in-human study with only 39 people, so the main goal is safety, not effectiveness. Many promising drugs fail in later stages, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Research SA
RECRUITINGAdelaide, 5000, Australia
-
Carolina BioOncology Institute, LLC
RECRUITINGHuntersville, North Carolina, 28078, United States
-
MUSC Hollings Cancer Center
RECRUITINGCharleston, South Carolina, 29425, United States
-
Mary Crowley Cancer Research
RECRUITINGDallas, Texas, 75230, United States
-
Monash Medical Centre Clayton
RECRUITINGClayton, 3168, Australia
-
Norton Cancer Institute PARENT
RECRUITINGLouisville, Kentucky, 40202, United States
-
Rhode Island Hospital
RECRUITINGEast Providence, Rhode Island, 02903, United States
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
Scientia Clinical Research
RECRUITINGRandwick, 2031, Australia
-
South Texas Accelerated Research Therapeutics (START), LLC
RECRUITINGSan Antonio, Texas, 78229, United States
-
Tasman Oncology Research Ltd
RECRUITINGSouthport, Queensland, 4215, Australia